Last reviewed · How we verify
Prevention of CMV Disease After Kidney-Pancreas Transplantation — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Valcyte | VALGANCICLOVIR | Cheplapharm | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 2001-01-01 | ||
| Cytovene | GANCICLOVIR | Roche Palo | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | Metabotropic glutamate receptor 1 | 1989-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Cheplapharm · 1 drug in Prevention of CMV Disease After Kidney-Pancreas Transplantation
- Roche Palo · 1 drug in Prevention of CMV Disease After Kidney-Pancreas Transplantation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of CMV Disease After Kidney-Pancreas Transplantation:
- Prevention of CMV Disease After Kidney-Pancreas Transplantation treatment updates — RSS
- Prevention of CMV Disease After Kidney-Pancreas Transplantation treatment updates — Atom
- Prevention of CMV Disease After Kidney-Pancreas Transplantation treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of CMV Disease After Kidney-Pancreas Transplantation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-cmv-disease-after-kidney-pancreas-transplantation. Accessed 2026-06-10.
Related
- Prevention of CMV Disease After Kidney-Pancreas Transplantation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing